Yu Yu Kirichenko, I S Ilgisonis, A D Chernichkina, A V Palienko, O I Buduscheva, N N Pakhtusov, N V Khabarova, Yu N Belenkov
{"title":"[4‑Year Experience of the Cardio-Oncology Center of Sechenov University: Single-Center Epidemiological Study].","authors":"Yu Yu Kirichenko, I S Ilgisonis, A D Chernichkina, A V Palienko, O I Buduscheva, N N Pakhtusov, N V Khabarova, Yu N Belenkov","doi":"10.18087/cardio.2024.10.n2768","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>To present the four-year experience and the accomplishments of the Scientific and Practical Cardio-Oncology Center of the Sechenov University.</p><p><strong>Material and methods: </strong>The records of patients referred for cardio-oncology consultation from January 2020 through March 2024 were retrospectively analyzed. The patients' cardiovascular (CV) status was assessed at baseline and after optimizing the cardiac therapy during the antitumor treatment. The endpoints were the completion of all antitumor therapy courses and the level of overall and CV mortality.</p><p><strong>Results: </strong>Among 233 enrolled patients (66% women), a considerable part belonged to the group of high/very high cardio-oncological risk (n=134, 57%). Various cardiovascular toxicities were observed in 22% of patients. At baseline, these patients significantly more frequently had heart failure and ischemic heart disease as well as previous radiation and chemotherapy. After the optimization of cardiac therapy, 88% of patients successfully completed all scheduled treatments. The overall mortality, including the CV mortality, was 14% (n=7).</p><p><strong>Conclusion: </strong>Creation of cardio-oncological services allows considerably reducing the probability of adverse CV events during the antitumor therapy and successfully completing all scheduled treatments in most patients..</p>","PeriodicalId":54750,"journal":{"name":"Kardiologiya","volume":"64 10","pages":"32-39"},"PeriodicalIF":0.5000,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kardiologiya","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.18087/cardio.2024.10.n2768","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Aim: To present the four-year experience and the accomplishments of the Scientific and Practical Cardio-Oncology Center of the Sechenov University.
Material and methods: The records of patients referred for cardio-oncology consultation from January 2020 through March 2024 were retrospectively analyzed. The patients' cardiovascular (CV) status was assessed at baseline and after optimizing the cardiac therapy during the antitumor treatment. The endpoints were the completion of all antitumor therapy courses and the level of overall and CV mortality.
Results: Among 233 enrolled patients (66% women), a considerable part belonged to the group of high/very high cardio-oncological risk (n=134, 57%). Various cardiovascular toxicities were observed in 22% of patients. At baseline, these patients significantly more frequently had heart failure and ischemic heart disease as well as previous radiation and chemotherapy. After the optimization of cardiac therapy, 88% of patients successfully completed all scheduled treatments. The overall mortality, including the CV mortality, was 14% (n=7).
Conclusion: Creation of cardio-oncological services allows considerably reducing the probability of adverse CV events during the antitumor therapy and successfully completing all scheduled treatments in most patients..
期刊介绍：
“Kardiologiya” (Cardiology) is a monthly scientific, peer-reviewed journal committed to both basic cardiovascular medicine and practical aspects of cardiology.
As the leader in its field, “Kardiologiya” provides original coverage of recent progress in cardiovascular medicine. We publish state-of-the-art articles integrating clinical and research activities in the fields of basic cardiovascular science and clinical cardiology, with a focus on emerging issues in cardiovascular disease. Our target audience spans a diversity of health care professionals and medical researchers working in cardiovascular medicine and related fields.
The principal language of the Journal is Russian, an additional language – English (title, authors’ information, abstract, keywords).
“Kardiologiya” is a peer-reviewed scientific journal. All articles are reviewed by scientists, who gained high international prestige in cardiovascular science and clinical cardiology. The Journal is currently cited and indexed in major Abstracting & Indexing databases: Web of Science, Medline and Scopus.
The Journal''s primary objectives
Contribute to raising the professional level of medical researchers, physicians and academic teachers.
Present the results of current research and clinical observations, explore the effectiveness of drug and non-drug treatments of heart disease, inform about new diagnostic techniques; discuss current trends and new advancements in clinical cardiology, contribute to continuing medical education, inform readers about results of Russian and international scientific forums;
Further improve the general quality of reviewing and editing of manuscripts submitted for publication;
Provide the widest possible dissemination of the published articles, among the global scientific community;
Extend distribution and indexing of scientific publications in major Abstracting & Indexing databases.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
